To examine 143 diabetes risk single nucleotide polymorphisms (SNPs), identified from genome-wide association studies, in association with breast cancer (BC) incidence and subsequent mortality. A population-based sample of Caucasian women with first primary invasive BC (n = 817) and controls (n = 1021) were interviewed to assess diabetes status. Using the National Death Index, women with BC were followed for >18 years during which 340 deaths occurred (139 BC deaths). Genotyping was done using DNA extracted from blood samples. We used unconditional logistic regression to estimate age-adjusted odds ratios and 95% confidence intervals (CIs) for BC incidence, and Cox regression to estimate age-adjusted hazard ratios and CIs for all-cause and BC-specific mortality. Twelve SNPs were associated with BC risk in additive genotype models, at α = 0.05. The top three significant SNPs included SLC30A8-rs4876369 (P = 0.0034), HHEX-rs11187146 (P = 0.0086), and CDKN2A/CDKN2B-rs1333049 (P = 0.0094). Diabetes status modified the associations between rs4876369 and rs2241745 and BC incidence, on the multiplicative interaction scale.
TCF2/HNF1B-rs3094508, P = 0.0344) mortality in additive genotype models, at α = 0.05. Genetic polymorphisms that increase the risk of developing diabetes may also increase the risk of developing and dying from BC.
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breast cancer, diabetes, genetics, incidence, mortality, single nucleotide polymorphisms, survival 1 | INTRODUCTION Over 11 million women aged ≥18 years were living with diagnosed diabetes in the United Sates (US) in 2015. 1 Diabetes is a known risk factor for heart disease, stroke, nephropathy, and neuropathy and cancers of the liver, pancreas, endometrium, and colon/rectum. 2 Accumulating epidemiologic evidence suggests that diabetes may also increase the risk of developing breast cancer (BC), the most frequently diagnosed cancer among women in the US. 3 A meta-analysis of five case-control and 15 cohort studies reported a 20% increased risk of developing BC among women with diabetes, compared to those without diabetes. 4 Diabetes and BC are both complex multifactorial diseases that share several common predisposing risk factors, including age, overweight/obesity, alcohol consumption, and physical inactivity. 1, 5, 6 A number of biological mechanisms that focus on the underlying pathologic characteristics of diabetes have been proposed to explain a potential causal association between diabetes and carcinogenesis. 5 High circulating levels of glucose (ie, hyperglycemia), for example, may facilitate neoplastic proliferation due to high rates of glucose uptake required and adopted by many cancers. 5, 7 Furthermore, high circulating levels of insulin (ie, hyperinsulinemia) may promote carcinogenesis directly through insulin receptor-mediated mitogenesis, 5, 8, 9 and indirectly through the reduced hepatic transcription of the insulinlike growth factor binding protein-1 (IGFBP-1) gene, 10 which results in increased circulating levels of free bioactive IGF-1, a potent mitogen of human breast MCF-7 cells. 11 Insulin resistance is also associated with reduced levels of sex hormone binding globulin (SHBG) and thus increases in bioavailable estrogen, although the directionality of association has not been established. 12 Given the proliferative effects of insulin on BC cells, hyperinsulinemia is also hypothesized to increase risk of mortality following cancer. 5 To date, few studies 13 have investigated diabetes status in relation to mortality following BC. While studies consistently report a 40-50% increase in risk of all-cause mortality following BC, 13, 14 results
of BC-specific mortality have been mixed. [15] [16] [17] However, diabetes has also been associated with more advanced stage at BC presentation, 18, 19 and for those with diabetes, BC treatment tends to be less aggressive and causes more adverse effects. 13, 19 Despite observational studies linking diabetes to BC, a few studies [20] [21] [22] have examined a small number (≤40) of diabetes risk single nucleotide polymorphisms (SNPs) in association with risk of incident BC and subsequent mortality. Given that diabetes is strongly influenced by genetic factors, 23 we examined the associations between 143 SNPs in or near 29 genes identified from genomewide association studies of diabetes risk, and BC incidence and subsequent mortality among participants of a population-based study of BC.
| MATERIALS AND METHODS

| Study population
This study included 1838 Caucasian women from the Long Island Breast Cancer Study Project (LIBCSP), a population-based study initiated as a case-control study and then continued as a follow-up study. The LIBCSP study protocol was approved by the Institutional Review Boards of all participating institutions and written informed consent was obtained from participants prior to data collection.
| Case-control design
Details of the LIBCSP case-control design have been previously reported. 24 In brief, adult women with a first diagnosis of in situ or invasive BC during August 1, 1996 and July 31, 1997 were identified using a rapid reporting system established for the LIBCSP. Approximately 82.1% (n = 1,508) of eligible women with BC completed a comprehensive 100-min interviewer-administered questionnaire, on average within 3 months of diagnosis (25th percentile = 1.2 months, 75th percentile = 4.0 months). Seventy-three percent of BC participants provided blood samples, of which the majority were collected prior to chemotherapy (77.2%). Medical records were abstracted to obtain information on estrogen and progesterone receptor (ER and PR, respectively) status and first course of treatment. The mean age at BC diagnosis among the women included in this study was 59
(range = 25.1-91.9). The majority of women with BC were postmenopausal at diagnosis (68.1% 
| Diabetes status
Diabetes status was assessed by self-report as part of the case-control interview. Participants were asked whether they had ever been told by a physician that they had diabetes, sugar diabetes, or high blood sugar. 15 If participants responded in the affirmative, they were also asked the year in which the doctor first told them they had diabetes and whether they had been prescribed medication for their diabetes.
Five women (three with BC and two without BC) were missing information on diabetes status. The prevalence of diabetes was 6.9%
among women with BC, and 7.0% among women without BC.
| SNP selection and genotyping
We selected 158 polymorphisms in or near 29 genes for genotyping (Supplemental Table S1 ). These diabetes-related genes and SNPs were selected based on meta-analyses of genome wide association studies (GWAS), [27] [28] [29] [30] rs11708719 had a minor allele frequency <5% (4.55% in women with BC and 4.80% in women without BC). We examined the remaining 150
SNPs for linkage disequilibrium (LD) using the SNAP database based on
HapMap. 31 The following seven SNPs were excluded due to LD:
rs10010131, rs2046916, rs4712524, rs6744642, rs6769511, rs7748720, rs7923837. QC procedures resulted in 143 SNPs available for statistical analysis.
We used unconditional logistic regression in SAS software version 9.4 (SAS Institute, Inc., Cary, NC) to estimate age-adjusted odds ratios (ORs) and 95% confidence intervals (CIs) for the associations between the 143 SNPs and BC incidence. We used multivariable Cox regression in SAS to estimate age-adjusted hazard ratios (HRs) and 95% CIs of the associations between the 143 SNPs and all-cause and BC-specific mortality. For analyses of mortality, observations were censored at the end of follow-up in 2014, if alive. For analyses using BC-specific mortality as the outcome, non-BC deaths were censored at the time of death. For both BC incidence and mortality, we first examined each SNP using additive genotype models (ie, each variant copy is assumed to add to the expression of the phenotype). SNPs significantly associated with BC incidence or mortality at α = 0.05 were subsequently examined using co-dominant genotype models (ie, each variant copy is assumed to have an effect on the phonotype) with common homozygous genotypes defined among the women without breast cancer as the referent group. Although we present results for SNPs associated with BC incidence or mortality at α = 0.05, we also compared our results to a Bonferroni corrected α of 0.0003, to account for multiple comparisons given that we examined 143 SNPs. 32 SNPs associated with all-cause or breast cancer-specific mortality were also assessed for the proportional hazards assumption using Kaplan-Meier survival curves and Schoenfeld residuals; 33 there were no violations of the proportional hazards assumption. All logistic and Cox regression models were adjusted for age to account for frequency matching of women without BC to women with BC, but no other covariates, given that few factors are causally associated with genetic variants. 34 For BC incidence, all-cause mortality, and BC-specific mortality, we created three "risk scores" by summing the "at-risk" alleles significantly associated with each outcome at α = 0.05. The "at-risk"
allele was defined as the less common (variant) allele, unless the variant was inversely associated with breast cancer in this population, in which case the more common allele was defined as the "at-risk" allele. We categorized the continuous summary scores into tertiles based on the distributions in women without BC.
We examined diabetes status (yes vs no) as an effect modifier of the associations between SNPs found to be significantly associated and BC incidence or mortality. Multiplicative interactions were evaluated using likelihood ratio tests, comparing additive genotype models with diabetes-by-SNP cross-product terms against reduced models without the interaction terms. We did not examine interactions on the additive scale as we did not consider dominant genotype models.
3 | RESULTS
| Diabetes-related gene SNPs and breast cancer incidence
Twelve SNPs were significantly associated with the risk of developing BC in additive genotype models at α = 0.05 (Figure 1 ), but none were statistically significant at the Bonferroni-corrected alpha of 0.0003.
The most significant SNPs included rs4876369 (P = 0.0034), for which the heterozygous (vs common homozygous) genotype was associated with an OR of BC of 1.41 (95% CI = 1.12-1.76), and rs11187146
(P = 0.0086) and rs1333049 (P = 0.0094), for which the variant (vs common) homozygous genotypes were associated with ORs of BC of 2.06 (95% CI = 1.03-4.10) and 1.40 (95% CI = 1.08-1.82), respectively, in co-dominant genotype models (Table 1) . Variant (vs common)
homozygous genotypes of rs10830963 (P = 0.0125), rs6794209
(P = 0.0201), rs290494 (P = 0.0412), and rs2241745 (P = 0.0458) were inversely associated with BC incidence (Table 1 ). The highest (vs lowest) category of the summary score of "at-risk" alleles comprised of the sum of the 12 statistically significant SNPs was associated with a 109% increase in risk of BC (OR = 2.09, 95% CI = 1.64-2.66,
Diabetes status modified two SNP-BC incidence associations: 
| Diabetes-related gene SNPs and all-cause and breast cancer-specific mortality
Three SNPs (rs981042, P = 0.0032; rs1111875, P = 0.0361; and rs919275, P = 0.0488) were significantly associated with all-cause mortality in additive genotype models at α = 0.05 (Figure 2 ), but none were statistically significant at the Bonferroni-corrected alpha of 0.0003. In co-dominant genotype models, the rs981042-CA (vs CC) genotype was associated with worse overall survival in the KaplanMeier survival curves ( Figure 3 ) and with an all-cause mortality Cox model HR of 1.48 (95% CI = 1.09-2.01) ( Table 3 (Table 3) ;
however, in the Kaplan-Meier survival curves, the inverse association was only apparent for rs919275 ( Figure 3 ). The highest (vs lowest) category of summary score of "at-risk" alleles comprised of the sum of the three statistically significant SNPs, was associated with a Cox model HR of all-cause mortality of 1.52 (95% CI = 1.14-2.04,
Three SNPs (rs3218020, P = 0.0225; rs981042, P = 0.0246; and rs3094508, P = 0.0344) were significantly associated with BC-specific mortality in additive genotype models (Figure 2 ). In co-dominant genotype models, the variant (vs common) homozygous genotypes of rs3218020 and rs3094508 were associated with improved BCspecific survival in the Kaplan-Meier survival curves ( Figure 3 ) and with BC-specific mortality Cox model HRs of 0.57 (95% CI = 0.33-1.00) and 0.49 (95% CI = 0.26-0.90), respectively ( Table 3 ). The rs981042-CA (vs CC) genotype was associated with worse BC-specific mortality in the Kaplan-Meier survival curves ( Figure 3 ) and with a BC-specific mortality Cox model HR of 1.66 (95% CI = 1.05-2.61) ( Table 3 ). The highest (vs lowest) category of the summary score of "at-risk" alleles comprised of the sum of the three statistically significant SNPs was associated with a Cox model HR of BC-specific mortality of 2.26 (95% CI = 1.50-3.42, P = 0.0002).
Diabetes status did not modify the associations between rs981042, rs1111875, and rs919275 and all-cause mortality or between rs3218020, rs981042, and rs3094508 and breast cancerspecific mortality, on the multiplicative scale (Table 4) . SNPs inversely associated with breast cancer was rs10830963, an intron of MTNR1B (melatonin receptor 1B), which encodes one of two high affinity forms of a receptor for melatonin, a pineal gland hormone that regulates glucose metabolism by affecting circadian insulin secretion. 39 Given that these 12 SNPs consist of intron and intergene variants, their functional impact on BC risk is not clear. These SNPs may be in LD with functionally relevant SNPs not included in our study or they may affect gene function by altering the stability, splicing, or localization of the mRNA. 40 In a previous large study of type 2 diabetes susceptibility variants and the risk of developing BC in women of European ancestry, one SNP (TCF7L2-rs7903146) was positively associated and two (FTOrs9939609 and PRC1-rs8042680) were inversely associated with BC risk. 20 In our study, we included rs7903146, an intron variant of TCF7L2 (transcription factor 7 like 2); however, we found no association between this SNP and either risk of developing BC or mortality after BC. It is possible that our study lacked adequate power to detect this association, given that the study by Zhao et al. reported
an OR estimate for the risk of developing BC of 1.04 (95% CI = 1.02-
1.06). A second study of type 2 diabetes risk alleles and BC incidence in
Caucasian women reported positive associations for rs5945326 and rs1251809 and inverse associations for rs1111875 and rs10923931. 21 In contrast to the study by Hou et al., which reported worse overall survival and this association was modified by a history of diabetes. 46 In our study, the majority of women with BC were diagnosed with ER-positive BC, which limited our ability to examine effect modification by ER status. Individually, rs7403531 and rs391300 were positively associated with all-cause mortality in their study. 46 In contrast to our study, in their study rs4430796 was The "at-risk" allele was defined as follows: rs3218020: C allele; rs981042: A allele; rs3094508: A allele.
inversely associated with all-cause mortality. rs2028299 and rs1359790, SNPs not included in our study, were also significantly associated with BC recurrence/mortality. 46 Our study had several strengths, including a larger number of SNPs examined than studies published to date, a genetically homogenous population, and the use of existing resources from a population-based study of BC. Additionally, Mendelian randomization, the random assortment of alleles at the time of gamete formation, minimizes the potential for the association between diabetes risk variants and BC to be confounded by environmental factors. 34 The "at-risk" allele was defined as follows: rs3218020: C allele; rs981042: A allele; rs3094508: A allele.
